Please ensure Javascript is enabled for purposes of website accessibility

3 Things You Should Know About the Healthcare Sector

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Investing in healthcare isn't rocket science, but there are a few things you should understand.

Image source: Getty Images.

The multi-faceted healthcare sector is chock-full of opportunities for savvy investors. There are also plenty of potential pitfalls.

Understanding this complex sector of the economy can help you make better investing decisions. We asked three Motley Fool contributors to pick one important fact they think everyone should know before wading in. Here's what they had to say.

Demographics are your friend

Brian Feroldi: Did you know that every day between 2010 and 2029 roughly 10,000 baby boomers will turn 65? Or how about that, by 2050, the number of Americans age 65 or older is projected to reach 88.5 million, which is more than double the numbers we observed in 2010? Those are amazing statistics, and they should help to drive the demand for high-quality and affordable healthcare ever higher over the coming decades. That should be a nice tailwind for nearly every company that operates in the healthcare industry.

I think that one smart way to profit from the demographic shift is to buy a few shares of CVS Health (CVS -1.14%). After all, more elderly citizens will almost certainly lead to higher demand for pharmaceuticals, which plays into the company's strengths in two separate ways.

One, the company's retail pharmacy empire will undoubtedly see scripts and visits increase, especially since CVS is rolling out a nationwide network of in-store clinics that help treat minor ailments. Two, employers are going to need lots of help to control their spending on pharmaceuticals, which bodes well for future demand for CVS' pharmacy benefits-management business.

The demographic shift sets up CVS Health for decades of above-average revenue and profit growth. Shares currently are trading for only about 14 times forward earnings estimates, and they even offer up a dividend yield of 1.9%.

It's huge

Selena Maranjian: One thing that's good to know about the healthcare sector is just how huge and important it is. According to a 2016 report by Deloitte, healthcare spending makes up about 10% of global gross domestic product (GDP), while the Altarum Institute recently reported that in the U.S., healthcare spending makes up more than 18% of GDP. Per the Centers for Medicare & Medicaid Services (CMS), total national healthcare spending tops $3 trillion annually.

If you drill down to the individual level, it's still massive. Data for the Organization for Economic Cooperation and Development (OECD) showed an average of $3,453 in healthcare spending per capita in developed nations in 2015 -- and the U.S. is spending more than twice that, $8,713.

Investors digging more deeply into the numbers will find some interesting tidbits, such as: Per the Peterson-Kaiser Health System Tracker, as of 2013, the half of the population that spends the most on healthcare spends 97% of the money spent on healthcare. In other words, healthy people (such as most children and young people) spend very little on healthcare, while older and sicker folks generate some huge bills.

Specifically, "The 5% of people who spend the most on healthcare spend an average of around $43,000 annually; people in the top 1% have average spending of over $95,000. At the other end of the spectrum, the 50% of the population with the lowest spending accounted for 3% of all total health spending; the average spending for this group was $253."

Data like that can help investors understand, say, issues facing Obamacare, where younger and healthier people haven't yet enrolled in desired numbers, leaving insurers in the system with higher-than-anticipated costs. It can also point out the value in healthcare services targeting older and sicker people, such as dialysis services and nursing homes. It also drives home the importance of anticipating hefty healthcare costs in retirement. Fidelity Investments releases an annual estimate of how much a 65-year-old couple will spend out of pocket in retirement on healthcare, and their latest number is $260,000.

The price is a secret

Cory Renauer: If you're a biopharma investor, or just plain outraged by the rising prices of prescription drugs, you should understand that drug-pricing practices are extremely complex and opaque. Luckily, we have a graphic example from America's least favorite drugmaker at the moment, Mylan (MYL).

Image source: Mylan.

Mylan CEO Heather Bresch's attempt to shift blame for EpiPen price hikes to other players wasn't as ridiculous as it sounded. A follow-up press release gave us a rare glimpse into the secretive world of drug-pricing practices.

As Brian mentioned above, pharmacy benefit managers (PBMs), such as CVS Health, and Express Scripts (ESRX), negotiate discounts and rebates on behalf of insurers. The size of these rebates and discounts are considered proprietary information, and rarely disclosed -- even Mylan didn't include all the details in its attempt to defend itself.

Obviously, insurers aren't entitled to all the savings PBMs wrangle from drugmakers. We received a hint of how little is passed on this March when Anthem filed a lawsuit against Express Scripts claiming current pricing under a contract that began in 2009 exceeds competitive pricing by $13 billion.

ESRX Revenue (TTM) Chart

ESRX Revenue (TTM) data by YCharts.

Anthem's figure seems a bit distorted considering Express Scripts' fairly narrow margins. The $15 billion in damages Anthem is seeking would wipe out years of Express Scripts profits, and Anthem is just one of the PBM's clients.

What's clear, though, is the list price quoted for drugs can be much larger than the amount of revenue drugmakers record for each sale. If you're among those who are outraged by escalating drug prices, consider recent findings from IMS Health before shaking your fist at Big Pharma. According to the analytics firm, invoice prices for branded medicines rose 12.4% last year, but rebates and other discounts limited those price rises to an estimated 2.8%.

If you're investing in biopharma stocks, multiplying the list price of a newly approved drug by the number of potential patients can lead to some exciting figures. But, since surprisingly little of that will wind up in the drugmaker's pockets, you would be well advised to curb your enthusiasm.

Brian Feroldi has no position in any stocks mentioned. Cory Renauer has no position in any stocks mentioned. Selena Maranjian owns shares of Express Scripts. The Motley Fool owns shares of and recommends Express Scripts. The Motley Fool recommends CVS Health, and Mylan. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

CVS Health Stock Quote
CVS Health
CVS
$99.31 (-1.14%) $-1.14
Mylan Stock Quote
Mylan
MYL
Express Scripts Holding Company Stock Quote
Express Scripts Holding Company
ESRX

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
339%
 
S&P 500 Returns
110%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 10/06/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.